Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Standard COPD treatment includes older medications ... Dupixent is an antibody designed to block the IL-3 and IL-4 pathways. The drug currently has approvals in seven indications, most recently ...

FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the male ...

I love physiology, and even during medical school I thought pulmonary and critical care would be a potential career path. My ...

Not only are the neutrophils overstimulated, their pathways of activation and ... become more aware of their benefits in COPD. Corticosteroid treatment may be detrimental to the effectiveness ...

Zymeworks Inc. , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, ...

New Study Shows Promising Results for COPD Treatment Nov. 20 ... shedding light on potential pathways through which aging may promote lung cancer ... Folic Acid May Mitigate Link Between Lead ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

Long-term oxygen therapy (LTOT) is linked to reduced exacerbations and hospitalizations in COPD, ILD, and pulmonary hypertension.